LOGIN  |  REGISTER
Viking Therapeutics
Compass Therapeutics

Owens & Minor to Present at the Leerink Partners’ Healthcare Crossroads Conference on May 29, 2024

May 28, 2024 | Last Trade: US$12.00 1.25 -9.43

RICHMOND, Va. / May 28, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas. Owens & Minor is also hosting one-on-one meetings with investors at the conference.

Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations at least 10 minutes in advance to register for the live webcast of the discussion.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB